Knee Reconstruction devices Market to Reach USD 13.1 Bn by 2035

According to analysts at Vantage Market Research, the Global Knee Reconstruction devices Market size is worth USD 8.9 Billion in 2024 and is projected to reach USD 13.1 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 5.0% from 2025 to 2035. Key trends of market such as rising prevalence of knee disorders, growing aging population, technological advancement in knee surgeries, and focus on post-surgery rehabilitation. 

Market Overview

The market growing factors such as the growing adoption of technological developments and favorable reimbursement policies propel the knee reconstruction devices market. Many countries worldwide have become medical tourism points for knee reconstruction surgeries, as they provide quality treatment at affordable prices. Total joint replacement of a dysfunctional knee using artificial knee implants has been a reliable and efficient treatment method. By 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. As per the same source, around 32.5 million adults from the United States have osteoarthritis.

The increasing number of advancements in surgical techniques and implant materials, rapid adoption of minimally invasive surgeries, rising demand for personalized and patient-specific knee implants and technological advancements in knee reconstruction devices drives the growth rate of the market. Favorable compensation policies for knee reconstruction procedures, growing awareness about the benefits of knee reconstruction surgeries, increasing participation in sports and recreational activities leading to knee injuries and the growing number of strategic collaborations and partnerships between medical device manufacturers and healthcare providers further promote the knee reconstruction devices market growth.

Smith+Nephew introduces first of its kind handheld digital tensioning device for robotically-enabled total knee arthroplasty

• In April 2023, Smith+Nephew is the global medical technology company, today introduced its new CORI◊ Digital Tensioner - a purpose built device that lets surgeons measure the ligament tension in a knee prior to cutting bone. By enabling a surgeon to quantify joint laxity in the native knee and achieve an optimal ligament tensioning force, the CORI Digital Tensioner helps to reduce variability when balancing the knee in surgery.  This helps make surgical planning more objective versus other commercially available alternatives

Key Takeaways from the Report

• In 2024, based on the Product, the cemented implants category accounted for largest market share. The segment is driven by the increasing prevalence of knee-related disorders, an aging population, and advancements in implant materials and designs that enhance longevity and patient comfort
• In 2024, based on the End User, the hospitals category accounted for largest market share. The segment is driven by the availability of advanced facilities and the continuous growth of healthcare infrastructure within hospitals
• In 2024, North America dominated the market with largest market share. The market is driven by high incidence of knee related conditions such as arthritis and gout, and advancement in surgical technology and robotic navigation systems

Top Companies

• Aesculap Inc
• Zimmer Biomet
• MicorPort Scientific
• DePuy Synthes
• Medacta
• Stryker Corporation
• Smith & Nephew
• Tornier Inc.
• Exactech Inc.

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Zimmer Biomet Receives FDA Approval for Oxford® Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S.

• In November 2024, Zimmer Biomet Holdings, Inc. is a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford® Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing for cementless partial knee replacement (PKR).1 The Oxford Cementless Partial Knee allows surgeons to perform a PKR with improved fixation,2 better long-term implant survival rate2,3 and improved efficiency in the operating room4 (OR) compared to the Oxford Cemented Partial Knee procedure